AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Recordati Industria Chimica e Farmaceutica

Report Publication Announcement Mar 24, 2020

4056_rns_2020-03-24_b0ea6dc1-d6bd-48ab-85a0-d98ecf68c4ec.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

RECORDATI: PUBLIC DISCLOSURE

Milan, 24 March 2020 – Please be informed that, today, the Company made available to the public the following documents as approved by the Board of Directors on 18th March 2020: (i) the financial statements at, and for the year ended, 31 December 2019, (ii) the 2019 corporate governance report and ownership structure and (iii) the 2019 consolidated non-financial information disclosure pursuant to Legislative Decree n. 254 dated 30 December 2016.

The mentioned documents are published on the Company's website (www.recordati.it) and on the storage mechanism ().

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media Relations Marianne Tatschke Studio Noris Morano (39)0248787393 (39)0276004736, (39)0276004745

e-mail: [email protected] e-mail: [email protected]

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale VIA M. CIVITALI, 1 20148 MILANO, ITALIA TEL. (39) 0248787.1 FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v. REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150 CODICE FISCALE/P. IVA 00748210150 R.E.A. MILANO 401832

Talk to a Data Expert

Have a question? We'll get back to you promptly.